Boehringer and Lilly to assess empagliflozin for chronic kidney disease
Boehringer Ingelheim, in collaboration with Eli Lilly and Company, is set to evaluate empagliflozin in a new clinical outcomes trial to treat patients suffering from chronic kidney disease.
Authors: Avinash S, Singh VP, Agarwal AK, Chatterjee S, Araya V Abstract Background: Cystatin C is a low molecular weight protein produced by all nucleated human cells, with a stable production rate. Its levels are not influenced by inflammation, infections, hepatic or renal diseases, or by dietary or constitutional factors. We compared serum cystatin C and serum creatinine based predicting equations to estimate glomerular filteration rate (GFR) in type 2 diabetes mellitus, using the staging of chronic kidney disease (CKD) defined by the National Kidney Foundation. We also explored the relationship of urine albumin...
In conclusion, diagnosing HO is challenging for rheumatologists and physicians. Basic examinations of electrolyte balance and bone mineral density should be performed, as should tumor screening and a careful collection of patient medical history and drugs in young patients with unexplained thoracic or back pain and muscle weakness. Removing any secondary etiology, such as drugs may dramatically improve the patients clinical manifestations and result in an improved prognosis. PMID: 29904418 [PubMed]
Conclusions: Readily available electronic health record data can be used to predict impending acute kidney injury prior to changes in serum creatinine with excellent accuracy across different patient locations and admission serum creatinine. Real-time use of this model would allow early interventions for those at high risk of acute kidney injury.
Conclusion: Tropical diseases like malaria, dengue, and leptospirosis were the main factors responsible for ARDS. LIS, Modified LIS and PaO2/FiO2 ratio predicted outcome as well as need for mechanical ventilation. Renal failure, metabolic acidosis appeared to be good predictors of mortality. PMID: 29897698 [PubMed - in process]
Conclusions In this cross-sectional survey, reduced eGFR was strongly and independently associated with greater sedentary time. This risk was further heightened by the presence of diabetes and arthritis. Studies to determine causes for sedentary behavior and assess the feasibility and value of interventions to reduce sedentary time in CKD are needed.
AbstractAn iron scarcity often occurs in chronic kidney disease (CKD). Neutrophil gelatinase-associated lipocalin (NGAL), a biomarker of acute kidney injury, is associated with iron metabolism. The present study determined the association between serum NGAL and iron status in chronic kidney disease with anemia. A total of 154 adult CKD patients were divided into anemia and without anemia groups. The anemia groups were further subdivided into two groups based on the presence or absence of iron deficiency, defined as a transferrin saturation (TSAT)
Context: Soluble urokinase-type plasminogen activator (suPAR) is an inflammatory signal with pleiotropic biological effects depending on context and post-translational modifications. Recently, [Hayek, et al: Nat Med 2017; 23: 945–953] it has been found that there is a link between suPAR and renal disease in several guises, and a key question is whe ther it is a driver or a marker of renal disease, and if so of which types of kidney damage.Subject of Review: Circulating suPAR has been postulated to cause acute proteinuric kidney disease, specifically focal segmental glomerulosclerosis (FSGS), though both the anim...
I was interested to read the paper by Papademetriou et al1 published in the December 2017 issue of The American Journal of Medicine. I would like to congratulate the authors on their published results in the high-quality journal The American Journal of Medicine. However, several methodological issues should be considered.
Publication date: Available online 15 June 2018 Source:Pharmacological Research Author(s): Gregory J. Weber, Jaleyea Foster, Sathnur B. Pushpakumar, Utpal Sen Hypertension affects nearly one third of the adult US population and is a significant risk factor for chronic kidney disease (CKD). An expanding body of recent studies indicates that gut microbiome has crucial roles in regulating physiological processes through, among other mechanisms, one mode of short chain fatty acids (SCFA) and their target receptors. In addition, these SCFA receptors are potential targets of regulation by host miRNAs, however, the mechanisms th...